Teva Pharmaceutical Industries reported a revenue decline of 10%, in its first-quarter results, mainly related to the performance of its US generics business and lower sales of its top-selling specialty product, Copaxone (glatiramer acetate), a drug to treat multiple sclerosis. Read More

Bayer has agreed to sell additional crop science businesses to BASF for up to EUR 1.7 billion ($2 billion), following a 2017 sale pact between the companies. Bayer is in the process of acquiring Monsanto, an agrochemical and seed company, for $66 billion, which contains conditions, including the divestment of certain Bayer businesses, for regulatory approval. Read More

Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has agreed to acquire BeneVir Biopharm, a biopharmaceutical company specializing in developing oncolytic immunotherapies, for up to $1 billion ($140 million up front and $900 million in milestones). Read More

ANI Pharmaceuticals has agreed to acquire a portfolio of generic products and other assets from Amneal Pharmaceuticals, a generic-drug manufacturer, and Impax Laboratories, a specialty pharmaceutical company focused on controlled-release and specialty generics. The transaction is part of a mandated divestiture process in connection with Amneal’s merger with Impax. Read More

The FDA has issued a Complete Response Letter (CRL) to Sandoz, Novartis’ generics arm, regarding the biologics license application for its proposed biosimilar to Roche’s Rituxan (rituximab), a drug to treat certain cancers and autoimmune diseases. Rituxan is one of Roche's top-selling drugs with 2017 global sales of CHF 7.3 billion ($7.8 billion). Read More

WuXi Biologics, a CDMO of biologics, plans to invest EUR 325 million ($392 million) in a new biologics drug-substance manufacturing facility in Mullagharlin, Dundalk, County Louth, Ireland. Read More

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced a five-year corporate plan that highlights how the agency plans to address its regulatory functions post the UK’s exit from the European Union (i.e., Brexit). Read More

Shionogi & Co., an Osaka, Japan-headquartered pharmaceutical company, says it plans to establish a new wholly owned subsidiary, effective October 1, 2018, which will be in charge of manufacturing functions in the Shionogi group, including contract development manufacturing. Read More

STA Pharmaceutical, a subsidiary of the CDMO WuXi AppTec, has signed an agreement with the government of Shanghai, Jinshan District, China to build a new R&D center to support development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. Read More

CordenPharma, a CDMO of active pharmaceutical ingredients (APIs) and drug products, has expanded its commercial oligonucleotide API manufacturing at its site in Boulder, Colorado. Read More